362 related articles for article (PubMed ID: 23248097)
21. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
[TBL] [Abstract][Full Text] [Related]
22. Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention.
Cameron CM; Raghu V; Richardson B; Zagore LL; Tamilselvan B; Golden J; Cartwright M; Schoen RE; Finn OJ; Benos PV; Cameron MJ
medRxiv; 2024 May; ():. PubMed ID: 38766010
[TBL] [Abstract][Full Text] [Related]
23. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
[TBL] [Abstract][Full Text] [Related]
24. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer.
Guo M; Luo B; Pan M; Li M; Xu H; Zhao F; Dou J
Int Immunopharmacol; 2020 Nov; 88():106850. PubMed ID: 32777675
[TBL] [Abstract][Full Text] [Related]
25. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
Quiroga D; Aldhamen YA; Appledorn DM; Godbehere S; Amalfitano A
Cancer Immunol Immunother; 2015 Apr; 64(4):479-91. PubMed ID: 25655760
[TBL] [Abstract][Full Text] [Related]
26. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
27. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
28. Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention.
Haldar SD; Vilar E; Maitra A; Zaidi N
Cancer Prev Res (Phila); 2023 Sep; 16(9):483-495. PubMed ID: 37001882
[TBL] [Abstract][Full Text] [Related]
29. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
Guo M; You C; Dou J
Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model.
Gao FS; Zhan YT; Wang XD; Zhang C
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):353-357. PubMed ID: 30111221
[TBL] [Abstract][Full Text] [Related]
31. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
32. Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
Ravindranathan S; Nguyen KG; Kurtz SL; Frazier HN; Smith SG; Koppolu BP; Rajaram N; Zaharoff DA
Breast Cancer Res; 2018 Oct; 20(1):126. PubMed ID: 30348199
[TBL] [Abstract][Full Text] [Related]
33. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.
Rong Y; Qin X; Jin D; Lou W; Wu L; Wang D; Wu W; Ni X; Mao Z; Kuang T; Zang YQ; Qin X
Clin Exp Med; 2012 Sep; 12(3):173-80. PubMed ID: 21932124
[TBL] [Abstract][Full Text] [Related]
34. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
35. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
[TBL] [Abstract][Full Text] [Related]
37. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
38. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
40. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.
Gatti-Mays ME; Redman JM; Donahue RN; Palena C; Madan RA; Karzai F; Bilusic M; Sater HA; Marté JL; Cordes LM; McMahon S; Steinberg SM; Orpia A; Burmeister A; Schlom J; Gulley JL; Strauss J
Oncologist; 2020 Jun; 25(6):479-e899. PubMed ID: 31594913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
